BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28556233)

  • 1. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
    Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
    J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation.
    Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Wingard JR; Moreb JS
    Leuk Lymphoma; 2003 May; 44(5):815-20. PubMed ID: 12802919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH; Jung SK; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW; Kim DW; Kang ES
    Vox Sang; 2014 Nov; 107(4):407-15. PubMed ID: 25130876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution.
    Sauer S; Pavel P; Schmitt A; Cremer M; Kriegsmann M; Bruckner T; Jordan K; Wuchter P; Müller-Tidow C; Kriegsmann K
    BMC Cancer; 2020 Apr; 20(1):353. PubMed ID: 32334570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma.
    Song GY; Jung SH; Ahn SY; Jung SY; Yang DH; Ahn JS; Kim HJ; Lee JJ
    BMC Cancer; 2019 Jan; 19(1):59. PubMed ID: 30642286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.
    Sahin U; Demirer T
    J Clin Apher; 2018 Jun; 33(3):357-370. PubMed ID: 28980709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
    He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
    Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a quantitative prediction model for peripheral blood stem cell collection yield in the plerixafor era.
    Ishii A; Jo T; Arai Y; Oshima S; Kanda J; Kitawaki T; Matsui K; Niwa N; Nakagawa Y; Takaori-Kondo A; Nagao M
    Cytotherapy; 2022 Jan; 24(1):49-58. PubMed ID: 34654641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
    Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
    Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
    Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
    Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of plerixafor to mobilization regimens in autologous peripheral blood stem cell transplants does not affect the correlation of preharvest hematopoietic precursor cell enumeration with first-harvest CD34+ stem cell yield.
    Villa CH; Shore T; Van Besien K; Cushing M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1867-75. PubMed ID: 22796644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
    Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
    Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.
    Patterson AM; Zhang S; Liu L; Li H; Singh P; Liu Y; Farag SS; Pelus LM
    Stem Cell Rev Rep; 2021 Dec; 17(6):2124-2138. PubMed ID: 34510361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of laboratory parameters for optimal autologous peripheral blood stem cell collection from lymphoma and myeloma patients.
    Kong JH; Hu Y; Kong SY; Lee SN; Eom HS; Lee H; Lee E; Shim H
    J Clin Apher; 2021 Feb; 36(1):135-142. PubMed ID: 33247855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.